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Intraoperative pathologyAbstract Background: Nipple–areola sparing mastectomy (NSM) with immediate implant
reconstruction is an option for patients with non-locally advanced breast cancer. The predic-
tion of occult tumour involvement of the nipple–areola complex (NAC) may help select can-
didates to NSM.
Patients and methods: We prospectively recorded clinical and pathological data, magnetic res-
onance imaging (MRI) results and intraoperative pathological assessments of the subareolar
(SD) and proximal nipple ducts (ND) of 112 consecutive breast cancer patients scheduled for
NSM. All parameters were correlated with final pathological NAC assessment by univariate
and multivariate analysis.
Results: Thirty-one patients (27.7%) had tumour involvement of the NAC. At univariate anal-
ysis, age (p = 0.001), post-menopausal status (0.003), tumour central location (p = 0.03),
tumour–NAC distance measured by MRI (p = 0.000) and intraoperative pathologic assess-
ment (SD + ND) (p = 0.000) were significantly correlated with NAC involvement. At multi-
variate analysis, only MRI tumour–NAC distance (p = 0.008) and menopausal status
(p = 0.039) among all preoperative variables retained statistical significance. The sensitivity
and specificity of MRI tumour–NAC distance were 32.2% and 88.6% and those of
R. Ponzone et al. / European Journal of Cancer 51 (2015) 1882–1889 1883intraoperative pathologic assessment were 46.7% and 100%, respectively. Sensitivity, speci-
ficity and accuracy of the double assessment (MRI plus intraoperative pathology) were
50.0%, 96.2% and 84.1%, respectively.
Conclusion: Intraoperative pathologic assessment and tumour–NAC distance measured by
MRI are the most important predictors of occult NAC involvement in breast cancer patients.
A negative pathological assessment and a tumour–NAC distanceP 5 mm allow optimal dis-
crimination between NAC positive and NAC negative cases and may serve as a guide for the
optimal planning of oncological and reconstructive surgery.
 2015 Elsevier Ltd. All rights reserved.1. Introduction
The most important evolution of breast cancer sur-
gery after the introduction of sentinel node dissection
is likely represented by the progressive reduction of
the amount of breast skin that is removed during mas-
tectomy. The shift towards more conservative types of
mastectomy began with the introduction of
implant-based immediate reconstruction in the early
1990s [1]. The term skin-sparing mastectomy (SSM)
was originally introduced to describe the removal of
breast and nipple–areola complex (NAC) as well as
the previous biopsy scars through a pre-planned incision
with the preservation of the remaining skin envelope of
the breast [2]. Further refinements of SSM combined
with immediate breast reconstruction allowed superior
cosmetic outcomes and rapidly made it the preferred
option for early breast cancer patients undergoing mas-
tectomy [3]. This change of practice occurred all over the
world despite lack of randomised studies proving the
oncological safety of SSM. Indeed, several observational
studies and a metanalysis [4,5] suggest that SSM is not
significantly different from total mastectomy in terms
of local recurrence rates and most scientific societies
have endorsed SSM for early breast cancer patients [6].
Although NAC involvement has been reported to
occur in up to 58% of breast cancer patients [7], recent
data suggest that it is actually less frequent [8].
Therefore, a new type of mastectomy with the preserva-
tion of the NAC, named ‘NAC sparing mastectomy’
(NSM), has been proposed as a possible alternative in
selected breast cancer patients undergoing immediate
reconstruction [9,10] or in BRCA1/2 mutation carriers
opting for prophylactic surgery [11,12]. Several institu-
tions have now adopted NAC sparing mastectomy in
breast cancer patients and early follow up data on onco-
logical safety and postoperative complications are reas-
suring [13].
In patients who are candidates to NSM, preoperative
assessment of the NAC helps optimal surgical planning,
while intraoperative awareness of NAC infiltration
allows the conversion to a SSM, avoiding the need of
a second delayed surgery to remove the NAC. The like-
lihood of NAC involvement has been associated with
several tumour characteristics such as retroareolarlocation, distance from the NAC, size, multifocality/mul
ticentricity, grade, lympho-vascular invasion, extensive
intraductal component and lymph-nodal status [14–17].
We recently showed that tumour–NAC distance
measured by magnetic resonance imaging (MRI) of
the breast is the key preoperative predictor of NAC
involvement in a series of total mastectomies performed
at our Institution [18]. Furthermore, intra-operative
evaluation of the retro-areolar tissue is very sensitive
for detecting cancer cells in the sub-areolar tissue with
a false negative rate as low as 11.8% [19].
In the current study, we prospectively assessed the
relative contribution and usefulness of breast MRI and
intraoperative pathological assessment of the NAC for
the prediction of NAC involvement and surgical plan-
ning in a consecutive series of NSM.
2. Patients and methods
Since January 2010 to January 2012 we enrolled all
patient candidates to NAC sparing mastectomy into a
protocol approved by the Institutional Review Board
that included preoperative MRI and intra-operative
assessment of NAC status. Potential candidates to
NAC sparing mastectomy were all patients affected by
invasive or in situ ductal carcinoma without evident clin-
ical and radiological involvement of the NAC and/or
the skin, not amenable to breast conserving surgery
and willing to undergo immediate implant-based recon-
struction. Exclusion criteria were patients with locally
advanced tumours not undergoing or not responding
to preoperative chemotherapy, inflammatory breast can-
cer and Paget’s disease of the nipple. Patients with bilat-
eral malignancy could be included, but not those
undergoing prophylactic mastectomy or mastectomy
performed for non-malignant lesions and lobular carci-
noma in situ of the breast. All patients signed a written
informed consent. All clinical (age, menopausal status,
tumour location, nodal involvement), radiological
(tumour–NAC distance, tumour largest diameter and
multifocality) and pathological (tumour size, histologic
grade and tumour marker status, multifocality/multi-
centicity, in situ component, nodal involvement) data
were recorded in a prospectively maintained institu-
tional database.
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MRI examinations were acquired with a 1.5T equip-
ment and dedicated phased-array 8-channel coil (HDx
Signa Excite, GE HealthCare Milwaukee, WI, USA),
following the recommended technical requirements
[20]. In particular, the dynamic study was performed
by a 3D Vibrant sequence (slice thickness 2.6 mm;
matrix 416x416; temporal resolution 90 s) acquired
before and five times after intravenous contrast agent
administration (0.1 mmol/kg of Gadobenate
Dimeglumine, Bracco Imaging, Milan, Italy) at a flow
rate of 2 ml/s. Multiplanar reconstructions (MPR)
obtained from subtracted images (1st and 5th
post-contrast series – pre-contrast acquisition) were
used to assess prospectively the diameter of the lesion,
which was defined as the maximum extent of suspicious
enhancement. In the case of bifocal, multifocal or mul-
ticentric lesions, these were considered as a single mass
and the reference measure reflected the whole area
occupied in the breast. A conventional measure of
the larger tumour foci was also recorded in this group.
MRI Tumour NAC–distance was measured by elec-
tronic calipers, on both axial and sagittal Maximum
Intensity Projection (MIP) images. Both these measure-
ments, as well as the minimum distance between the
base of the NAC and the nearest margin of the lesion
[18] were evaluated to predict the likelihood of NAC
involvement.2.2. Intraoperative NAC assessment
During NAC sparing mastectomy, the maximum
amount of breast tissue was excised while raising the
NAC as a full-thickness skin flap. In brief, the duct bun-
dle was exposed, a cut was made where it entered the
nipple and a 1 cm-thick disc of tissue containing the
ducts just beneath the NAC (subareolar ducts or SD)
was biopsied and orientated. A second biopsy was taken
by inverting the nipple on a finger and by sampling the
ducts contained in its central portion (proximal nipple
ducts o ND). Both biopsies were sent for frozen section
analysis.2.3. Definition of NAC involvement
NAC involvement was defined by the presence of
invasive ductal/lobular carcinoma and/or ductal carci-
noma in situ/ductal intraepithelial neoplasia (DIN1c–
DIN3), but not of lobular carcinoma in situ/lobular
intraepithelial neoplasia (LIN1–LIN3). Only if either
of the samples revealed malignancy at intra-operative
or definitive histology the NAC was removed respec-
tively at the time of mastectomy or as a second surgery
under local anaesthesia.2.4. Statistical analysis
The quantitative variables were compared with the
Pearson chi-square test or Fisher’s exact test.
Qualitative variables were compared using the analysis
of variance. The normality of variables was tested by
the Kolmogorov–Smirnov procedure. Variables not
normally distributed were analysed using the
non-parametric Mann–Whitney U test. Univariate and
multivariate analyses using logistic regression models
were undertaken to predict involvement of the NAC
(yes/no) on the basis of clinical characteristics, MRI
findings, intra-operative and postoperative pathological
findings. Variables included tumour histologic type, mul
tifocality/multicentricity, node positivity, lymphovascu-
lar invasion, grade, hormone receptor status,
HER-2/neu expression, proliferation markers (Ki-67),
in situ component and extensive intraductal component
(defined as P25% of the area within the invasive carci-
noma being ductal carcinoma in situ). A receiving oper-
ating characteristic (ROC) curve was constructed and
the best cut-off point was searched for optimal balance
between sensitivity and specificity of tumour–NAC dis-
tance for the sagittal, axial, minimum and mean dis-
tances from the NAC. A p value of 60.05 was
considered statistically significant. All statistical analy-
ses were performed by SPSS for Windows.3. Results
Overall, 27.7% of the patients had NAC involvement
at definitive pathology. Intraoperative frozen section
analysis correctly identified NAC involvement in 14
out of 31 cases (false negative rate = 54.5%). At univari-
ate analysis, older age (p = 0.001), postmenopausal sta-
tus (p = 0.003) central tumour location (p = 0.03), nodal
involvement (p = 0.002), low Ki-67 expression
(p = 0.006), MRI tumour–NAC mean distance
(p = 0.000) and intra-operative pathological positivity
(p = 0.000), were all significantly associated with NAC
involvement at definitive pathology. Tumour involve-
ment was most frequent in SD than ND (43.3% versus
20%), and ND were the only positive ducts in one
patient (Table 1).
A multivariate analysis including all variables obtain-
able pre-operatively (menopausal status, clinical nodal
status, central tumour location, tumour–NAC distance
at MRI, histological type, grading and
immuno-histochemical profile) revealed that only MRI
tumour-NAC distance (p = 0.008) and menopausal sta-
tus (p = 0.039) provided independent information on
the likelihood of NAC involvement at definitive
histology.
A ROC curve was constructed for sagittal, axial, min-
imum and mean tumour–NAC distances (Fig. 1).
Table 1
Univariate analysis of tumour characteristics associated with involvement of NAC.






Age (mean) 46 y 53 y 0.001
Premenopausal status 60 (71.4%) 14 (42.4%) 0.003
Received neoadjuvant therapy 6 (7.1%) 1 (3%) NS
Tumour central location 1 (1.3%) 3 (10%) 0.03
Nodal involvement (clinical and/or cytological) 25 (29.8%) 16 (48.5%) NS
Radiological (preoperative)
Tumour size on MRI (mean) 28.4 mm 28.7 mm NS
Distance of tumour from NAC on MRI (mean)a 33.6 mm 19.3 mm 0.000
Multifocal or multicentric disease on MRI 41 (72.9%) 20 (87.0%) NS
Pathological (intraoperative)
Subareolar nipple ducts (SD) involvement 0 (0%) 13 (43.3%) 0.000
Proximal nipple ducts (ND) involvement 0 (0%) 6 (20%) 0.000
SD and/or ND involvement 0 (0%) 14 (46.7%) 0.000
Pathological (definitive)
Path T2 or greater 31 (37.3%) 16 (48.5%) NS
Aggregate size of lesion (only invasive component) (mean) 17.0 mm 20.9 mm NS
Histologic intraductal cancer 15 (18.5%) 4 (12.9%) NS
Histologic infiltrating lobular cancer 11 (13.1%) 4 (12.1%) NS
Multifocal or multicentric disease 25 (29.8%) 10 (30.3%) NS
Nodal involvement 29 (38.2%) 20 (62.5%) 0.02
Lymphovascular invasion: positive 35 (47.9%) 18 (62.1%) NS
Grade: high 43 (57.3%) 13 (40.6%) NS
ER: positiveb 63 (79.7%) 28 (87.5%) NS
PR: positiveb 56 (70.9%) 25 (75.8%) NS
HER-2/neu: positived 13 (20%) 3 (10.3%) NS
Ki-67: highc 54 (87.1%) 18 (62.1%) 0.006
In situ component: present 34 (40.5%) 17 (51.5%) NS
NAC nipple–areolar complex, MRI magnetic resonance imaging.
a A mean of sagittal, axial and minimum distances was used *G3; ER oestrogen receptor, PR progesterone receptor.
b PositiveP 1% of stained cells.
c High: >20%, of stained cells.
d Positive: 3+ or amplified.
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tumour–NAC distance (Area Under the
Curve = 0.716) was slightly superior to either the
sagittal or minimum distance measurements.
Different cut-offs of the tumour–NAC distance for
the prediction of NAC–involvement at MRI were tested
(Table 2). If the cut-off of tumour–NAC distance by
MRI was set at 10 mm, all diagnostic parameters of
the combined assessment of the NAC (MRI plus intra-
operative pathology) were superior to MRI alone,
whereas only sensitivity (53.6% versus 46.7%) was
improved by the combined assessment as compared to
intraoperative pathology alone. Similarly, if the cut-off
was lowered at 5 mm, all diagnostic parameters were
superior for the combined assessment as compared to
MRI alone except for the negative predictive value
(84.4% versus 87.6%), whereas only sensitivity (50.0%
versus 46.7%) was superior for the combined assessment
as compared to intraoperative pathology alone
(Table 3).4. Discussion
The rates of tumour NAC involvement in the litera-
ture are inconsistent [14–21] likely due to different
pathological protocols for NAC evaluation and variable
accuracy of clinical and pathological data collection.
For example, a recent systematic review of the literature
showed that only 6.4% of the nipple cores of 2477 NAC
sparing mastectomies were involved with tumour [13].
This is less than half of the rate (14.2%) of NAC involve-
ment shown in a study of 2323 consecutive total mastec-
tomy specimens with grossly unremarkable nipples
evaluated at final pathology by sagittal sections through
the entire nipple and sub-areolar tissue [8]. Such a differ-
ence in the rate of NAC involvement in two large retro-
spectives studies likely reflects a selection bias towards
tumours of less advanced stage, and/or not involving
the central quadrant of the breast, or pre-neoplastic
lesions in patients submitted to NAC sparing mastec-
tomy as compared to total mastectomy [13].
Sensivity
1-Specificity
Sagial distance (AUC* = 0.699) 
Axial distance (AUC = 0.716)
Minimum distance (AUC = 0.703)
Mean distance (AUC = 0.708)
Reference line 
Fig. 1. Receiver Operating Characteristic (ROC) Curve for the performance of Sagittal, Axial, Minimum and Mean Tumour – Nipple Areola
Complex (NAC) distance at MRI to discriminate NAC involvement at definitive pathology. *AUC: Area Under the Curve.
Table 2
Diagnostic performance of different measurements of tumour–NAC distance by MRI.
Cut-off (mm) Sagittal Axial Minimum distance
65 610 620 65 610 620 65 610 620
Sens (%) 32.2 38.7 58 32.2 38.7 58.0 32.2 38.7 58.0
Spec (%) 88.0 85.0 79 88.6 85.8 75.3 88.6 85.0 74.6
PPV (%) 76.9 48.0 42,8 76.9 60.0 40.9 76.9 48.0 39.1
NPV (%) 78.7 78.1 81,4 87.6 80.2 80.2 78.7 78.1 80.3
Acc (%) 78.5 77.6 67 78.5 75.8 65.1 78.5 71.4 63.4
NAC: nipple–areola complex; MRI: magnetic resonance; Sens: sensitivity; Spec: specificity; PPV: positive predictive value; NPV: negative pre-
dictive value; ACC: accuracy.
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sparing mastectomies, 28.2% of the patients had a posi-
tive NAC, exactly twofold the rate that we detected in a
previous series of total mastectomies performed at our
institution (14%) [18]. Of note, both of our series were
constituted only by breast cancer patients and included
advanced and centrally located tumours. The higher
figure of NAC involvement in the current series maybe due to a pathological protocol specifically aimed at
assessing tumour infiltration of SD and ND, whereas
the protocol of our previous retrospective study relied
on a standard pathological assessment of the NAC
[18]. Indeed, other studies of NAC sparing mastectomy
with similar criteria of pathological assessment show
NAC involvement rates comparable to our current
study [19].
Table 3
Diagnostic performance of preoperative MRI assessment, intraoperative pathological assessment and combined assessment on the prediction of
NAC involvement.
Variable Sens (%) Spec (%) PPV (%) NPV (%) ACC (%)
Positive intraoperative histologya 46.7 100 100 84.0 86.0
MRI suspicious for NAC involvement (<5 mm)b 32.2 88.6 76.9 87.6 78.5
MRI suspicious for NAC involvement (<10 mm)b 38.7 85.8 60.0 80.2 75.8
MRI suspicious for NAC Involvement (<5 mm)b or positive intraoperative
histology
50.0 96.2 82.3 84.4 84.1
MRI suspicious for NAC Involvement (<10 mm)b or positive intraoperative
histology
53.6 88.6 62.5 84.3 79.4
a Subareolar and/or proximal nipple ducts.
b Axial tumour–NAC distance; MRI magnetic resonance imaging, NAC nipple–areolar complex; Sens: sensitivity; Spec: specificity; PPV: positive
predictive value; NPV: negative predictive value; ACC: accuracy.
Table 4
Studies on the prediction of NAC involvement by clinical (C), radiological (R) and intraoperative pathological (IP) assessment.
Author Nr. Pts. NAC involveda (%) Method of prediction Sens (%) Spec (%) PPV (%) NPV (%)
Schecter [14] 31 42 Rd 92 77 – 93
Loewen [16] 116 10 Rd 82 62 20 97
D’Alonzo [18] 39 14 Re 100 66 39 100
Billar [15] 392 16 C 61 86 45 92
37 Rc 38 96 62 89
37 C + R 48 97 69 93
Steen [19] 77 23 C 61 92 69 89
77 Re 56 95 77 88
77 C + Re 67 86 60 89
Stolier [17] 40 42.5 C + Rd 46.2 55.6 – –
57 IPb 88.2 100 – –
40 C + Rd + IPb 92.3 55.6 – –
Current study 112 Re,f 32.2 88.6 76.9 78.5
IP 46.7 100 100 86.0
Re + IPb 50.0 96.2 82.3 84.4
NAC: nipple areola complex; Pts.: patients; Sens: sensitivity; spec: specificity; PPV: positive predictive value; NPV: negative predictive value.
a At definitive pathology.




f Cut off: 5 mm.
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have explored the relationship of several preoperative
clinical and radiological parameters with the likelihood
of NAC involvement (Table 4). Unfortunately, clinical
criteria alone or in combination with mammography
(MX) and/or ultrasound scan (US) are associated with
variable and limited accuracy. For example, Stolier
et al. in a series of 58 breast cancer patients submitted
to total mastectomy reported that clinical and radiolog-
ical criteria had a sensitivity of 46.2% and a specificity of
55.6% and they found no added benefit from the inclu-
sion of such criteria to intra-operative histological
assessment of the NAC.
Data on preoperative assessment of the NAC by
MRI are more encouraging [18,19]. In our previous ret-
rospective study [18], by setting the cut-off of thetumour–NAC distance at 10 mm, MRI outperformed
MX in the prediction of NAC involvement with a sensi-
tivity of 100% versus 71% and a specificity of 66% versus
63% respectively. Moon et al. [21] in a retrospective
analysis of 51 breast cancers reported that NAC
enhancement at MRI had a sensitivity of 93.8% and a
specificity of 85.7%. In the current prospective study,
axial tumour–NAC distance at MRI with a cut-off set
at 10 mm had lower sensitivity (53.6% versus 100%),
but higher specificity (88.6% versus 66.0%) as compared
to our retrospective study [18], and its overall accuracy
was slightly increased by setting the cut-off at 5 mm
(78.5% versus 75.8%). To the best of our knowledge,
the only similar prospective study reported a sensitivity
of 28% and a specificity of 100% for the initial MRI
report, while a blinded re-review of all MRI scans
1888 R. Ponzone et al. / European Journal of Cancer 51 (2015) 1882–1889looking specifically for NAC involvement increased sen-
sitivity to 56% and lowered specificity to 95% [19].
Our study confirms the crucial role of intra-operative
pathological assessment of the NAC whose diagnostic
performance was as good as that of the combined assess-
ment (MRI + pathological), except for a lower sensitiv-
ity. Although not all pathology services provide
intra-operative diagnosis, our data suggest its impor-
tance to assure the best care of breast cancer patients
undergoing NAC sparing mastectomy. As SD and ND
were sent for frozen section analysis at the beginning
of the operation, results were always available before
the end of surgery and the overall operative time was
not increased. Although many authors examine only
the SD to decide whether the NAC can be preserved
or not, Steen et al. reported that 23% (4/17) of the cases
with positive nipple biopsy had negative SD and positive
ND [19]. Accordingly, we found that one out of 14
(7.1%) NAC-positive cases at intra-operative assessment
had only ND involvement. Therefore, we confirm that
double intra-operative assessment of SD and ND
increases the sensitivity of pathological intraoperative
assessment and we believe that it should be performed
to guide the management of the NAC.
We found that axial tumour–NAC distance at MRI is
the most accurate parameter to foresee the likelihood of
NAC involvement preoperatively and can improve the
sensitivity of pathological intraoperative assessment.
Preoperative assessment of the NAC is important as it
may help select the best surgical strategy and inform
the patients about the likelihood that the NAC could
be removed. Indeed, if the NAC is preserved,
one-stage breast reconstruction with immediate place-
ment of the prosthesis can be planned in selected cases.
Conversely, if the NAC has to be sacrificed, a two-stage
reconstruction with the placement of a skin expander is
generally preferable [22,23]. Furthermore, it is well
known that exhaustive preoperative information may
significantly influence the choices of breast cancer
patients on their favourite type of surgery [24] and
reduce their feelings of regret and dissatisfaction with
the operation [25].
In conclusion, our study suggests that MRI may offer
valuable information on the likelihood that the NAC
can be preserved, although the surgical management
isessentially guided by the intra-operative pathological
examination of both SD and ND. A limitation of the
study is the relatively short follow up, although no
tumour recurrences in the NAC have been detected so
far. If MRI and intraoperative pathology do not suggest
tumour involvement, the NAC can be preserved in
almost 85% of the cases and this combined assessment
appears as a reliable guide for patient information, sur-
gical planning and intra-operative management of the
NAC during mastectomy.Conflict of interest statement
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